Drug Approval | March 06, 2022
USFDA approves expanded use of Bristol Myers Opdivo
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
It plans launch various other health monitoring tools for smartphones, making existing devices obsolete
The CO2 Optimization module is one of the four modules (Product Costing, BoM Management, CO2 Optimization, Supplier Strategy) within the entire NDC Simulation Suite
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
At the new centre, customers get a real-time experience of the process of genetic testing and actionable plans in preventive healthcare under the expertise of certified genetic counsellors
State-of-the-art laboratory to support ingredient and specialty chemical innovation, product formulation application development and more sustainable solutions across Europe and beyond
Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16
Subscribe To Our Newsletter & Stay Updated
